← Back to Clinical Trials
Recruiting NCT05807555

NCT05807555 Longitudinal Evolution of Biomarkers of Dysautonomia and Inflammation During Sepsis in Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05807555
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Saint Etienne
Condition Sepsis
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2023-03-29
Primary Completion 2025-01-01

Trial Parameters

Condition Sepsis
Sponsor Centre Hospitalier Universitaire de Saint Etienne
Study Type OBSERVATIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age 1 Day
Max Age 17 Years
Start Date 2023-03-29
Completion 2025-01-01
Interventions
Ambulatory ECGBlood sample

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The Autonomic Nervous System (ANS) regulates the inflammatory response in real time, just as it controls heart rate and other vital functions. Many studies have investigated induced stimulation of the vagus nerve and its therapeutic effect in inhibiting TNFα (Tumor Necrosis Factor alpha) secretion, and therefore the risk of hypotension, septic shock, organ dysfunction during inflammation. While the anti-inflammatory effect of the autonomic nervous system on inflammation has been well studied, conversely, the effect of major inflammation on the balance of the autonomic nervous system is more difficult to understand. The inflammatory reflex could be overwhelmed and the regulatory centers of the brainstem dysregulated during situations of extreme inflammation.

Eligibility Criteria

Inclusion Criteria for cases group : * Hospitalization in a pediatric intensive care unit. * Presenting the sepsis criteria * Patient affiliated or entitled to a social security scheme * Holders of parental authority having received informed information about the study and having signed the consent form Exclusion Criteria for cases group : * Parents or legal guardians who do not speak French * Chronic or acute pathology that can alter autonomic balance (congenital heart disease, encephalopathy, neuropathy, acute pain, etc.) * Recent general anesthesia less than 48 hours old. (inclusion may be made beyond 48 hours from the last general anesthesia if the inclusion criteria remain present) * Taking treatments that can alter the ANS (β-blockers, etc.) or inflammation (NSAIDs, corticosteroids) Inclusion criteria for control group : * Patient affiliated or entitled to a social security scheme * Holders of parental authority having received informed information about the study and having sign

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology